Clinical trial

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

NCT03671538

Study summary

ClinicalTrials.gov

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: NA

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Anlotinib Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record pemetrexed Normalized identity: pemetrexed View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cisplatin Normalized identity: cisplatin View linked drug · Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2018-10-01

PhaseNA

Conditions

Non-squamous Non-small Cell Lung Cancerunresolved

Interventions

AnlotinibDRUG

pemetrexedDRUG · verified · RxNorm: pemetrexed

CisplatinDRUG · verified · RxNorm: cisplatin

Sponsors & collaborators

Lingyu Luolead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03671538 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.